Kevin R Flaherty
Overview
Explore the profile of Kevin R Flaherty including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
194
Citations
15722
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lough G, Abdulqawi R, Amanda G, Antoniou K, Azuma A, Baldi M, et al.
ERJ Open Res
. 2025 Mar;
11(2).
PMID: 40040894
Background: Suspected interstitial lung disease (ILD) patients may be referred to an ILD-specialist centre or a non-ILD-specialist centre for diagnosis and treatment. Early referral and management of patients at ILD-specialist...
2.
Wells A, Walsh S, Adegunsoye A, Cottin V, Danoff S, Devaraj A, et al.
Respir Res
. 2024 Dec;
25(1):448.
PMID: 39741294
Background: We sought consensus among practising respiratory physicians on the prediction, identification and monitoring of progression in patients with fibrosing interstitial lung disease (ILD) using a modified Delphi process. Methods:...
3.
Ryu M, Yun J, Kim K, Gentili M, Ghosh A, Sciurba F, et al.
BMC Genomics
. 2024 Dec;
25(1):1192.
PMID: 39695952
Background: Chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) are debilitating diseases associated with divergent histopathological changes in the lungs. At present, due to cost and technical limitations,...
4.
Kreuter M, Belloli E, Bendstrup E, Cerri S, Flaherty K, Shapera S, et al.
ERJ Open Res
. 2024 Dec;
10(6).
PMID: 39624387
Background: Acute exacerbations of fibrosing interstitial lung diseases (ILDs) are associated with high mortality. We used prospective data from the INBUILD trial to investigate risk factors for acute exacerbations and...
5.
Lancaster L, Cottin V, Ramaswamy M, Wuyts W, Gisli Jenkins R, Scholand M, et al.
Ther Adv Respir Dis
. 2024 Nov;
18:17534666241287307.
PMID: 39512136
This plain language summary shares results from a clinical study called INTEGRIS-IPF that was published in the in 2024. This study looked at a medicine called (beck-so-teh-grast) as a possible...
6.
Nathan S, Rajicic N, Dudenhofer R, Hussain R, Argula R, Bandyopadhyay D, et al.
Ann Am Thorac Soc
. 2024 Aug;
21(12):1661-1669.
PMID: 39141673
Inhaled nitric oxide (iNO) has been shown to result in benefits in moderate to vigorous physical activity (MVPA) in patients with fibrotic interstitial lung disease (f-ILD) receiving supplemental oxygen in...
7.
Pugashetti J, Kim J, Bose S, Adegunsoye A, Linderholm A, Chen C, et al.
Am J Respir Crit Care Med
. 2024 Jun;
210(5):639-647.
PMID: 38843133
Accelerated biological aging has been implicated in the development of interstitial lung disease (ILD) and other diseases of aging but remains poorly understood. To identify plasma proteins that mediate the...
8.
Lancaster L, Cottin V, Ramaswamy M, Wuyts W, Gisli Jenkins R, Scholand M, et al.
Am J Respir Crit Care Med
. 2024 Jun;
210(4):424-434.
PMID: 38843105
Idiopathic pulmonary fibrosis (IPF) is a rare and progressive disease that causes progressive cough, exertional dyspnea, impaired quality of life, and death. Bexotegrast (PLN-74809) is an oral, once-daily, investigational drug...
9.
Combs M, Belloli E, Gargurevich N, Flaherty K, Murray S, Galban C, et al.
J Heart Lung Transplant
. 2024 May;
43(9):1468-1477.
PMID: 38796045
Background: Chronic lung allograft dysfunction (CLAD) is the leading long-term cause of poor outcomes after transplant and manifests by fibrotic remodeling of small airways and/or pleuroparenchymal fibroelastosis. This study evaluated...
10.
Salisbury M, Flaherty K
Lancet Respir Med
. 2024 Apr;
12(7):500-501.
PMID: 38640935
No abstract available.